热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察 / Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19

ABSTRACT OBJECTIVE: In the early stage, through coronavirus epidemic attack on lung syndrome and mouse model in vivo experiments, Reyanning mixture has a significant therapeutic effect on human coronavirus pneumonia, this study further evaluates the treatment of new coronavirus pneumonia with Reyanning mixture (COVID-19) clinical efficacy provides a basis for clinical medication. METHODS: Selected from January 21, 2020 to March 2, 2020 in Shaanxi Provincial Infectious Disease Hospital, the Second Affiliated Hospital of Xi'an Jiaotong University, Songzi City People's Hospital of Hubei Province, and Yan'an Second People's Hospital, in line with the new The diagnostic criteria for coronavirus pneumonia were 54 patients with common type, including 28 in the treatment group, which were given Reyanning mixture on the basis of chemical drug treatment, and 26 patients in the control group, which were given chemical drug treatment. (Cough, fever, fatigue, chest tightness, runny nose, nasal congestion, headache) score, complete fever time (d), new coronavirus nucleic acid detection negative rate and chest CT remission rate. RESULTS: After treatment, the patients in the treatment group except for cough and fatigue, all other symptoms disappeared, dry throat pain, cough, fatigue, chest tightness, headache and other symptoms scores, compared with the control group, the difference was statistically significant (P <0.05) The median of complete fever in the treatment group was 3 days, which was 2 days shorter than that in the control group. The chest CT remission rate was 88.46% (23/26) in the treatment group and 73.91% (17/23) in the control group. The difference was not statistically significant; the negative rate of viral nucleic acid detection was 96.15% (25/26) in the treatment group, 60.87% (14/23) in the control group, and higher in the treatment group (P <0.01). CONCLUSION: Reyanning Mixture can improve the clinical symptoms of patients with new coronavirus pneumonia, shorten the clinical symptoms improvement time and nucleic acid negative time, and provide a basis for clinical treatment.